Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
SK Life Science, Inc.
Secondary Objectives of Part 1 (Dose Escalation Phase): 1. Characterize the pharmacokinetic (PK) profile of SKL27969 2. Evaluate the preliminary anti-tumor activity of SKL27969 Secondary Objectives of Part 2 (Dose Expansion Phase): 1. Investigate the safety and tolerability of SKL27969 at the RP2D in patients with selected tumor types 2. Characterize the PK of SKL27969
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted